{"preliminary_commentary":{"by_channel":{"x_thread":14,"bluesky_thread":3,"podcast":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06307431\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"INTerpath-004","nct_id":"NCT06307431","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=interpath-004-nct06307431. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"INTerpath-004","arms":[{"description":"Participants will receive intismeran autogene 1 mg via intramuscular (IM) injection every 3 weeks (Q3W) for up to 9 doses plus Pembrolizumab 400 mg via an intravenous (IV) infusion every 6 weeks (Q6W) for 9 cycles (up to \\~54 weeks). Each cycle is 6 weeks.","label":"Intismeran autogene + Pembrolizumab","type":"EXPERIMENTAL"},{"description":"Participants will receive placebo as an IM injection Q3W for up to 9 doses plus Pembrolizumab 400 mg via an IV infusion Q6W for 9 cycles (up to \\~54 weeks). Each cycle is 6 weeks.","label":"Placebo + Pembrolizumab","type":"ACTIVE_COMPARATOR"}],"collaborators":["ModernaTX, Inc."],"completion_date":{"date":"2032-06-08","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":272,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Intismeran autogene","otherNames":["mRNA-4157","V940"],"type":"BIOLOGICAL"},{"name":"Pembrolizumab","otherNames":["MK-3475","KEYTRUDA®"],"type":"BIOLOGICAL"},{"name":"Placebo","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2026-07-13","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase 2, Randomized, Double-blind, Clinical Study of V940 (mRNA-4157) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in the Adjuvant Treatment of Participants With Renal Cell Carcinoma (INTerpath-004).","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2028-01-08","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Disease-Free Survival (DFS)","timeFrame":"up to ~43 months"}],"references":[],"start_date":{"date":"2024-04-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004).","url":"https://clinicaltrials.gov/study/NCT06307431"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/interpath-004-nct06307431"}